ABEONA THERAPEUTICS INC. — Form 8-K
Filed August 13, 2026 · analyzed by the 8-K Agent
8-K
— Neutral
significance 48/100
What the filing says
Abeona reported Q2 2026 ZEVASKYN net revenue of $11.4M (up 31% from Q1's $8.7M), with 5 patients treated in Q2 and 3 in Q3 YTD; 12 total treatments completed since launch. The company secured CMS New Technology Add-On Payment (NTAP) status effective October 1, 2026, enabling supplemental Medicare reimbursement. Qualified treatment center (QTC) network expanded to seven sites, including CHOP, NewYork-Presbyterian/Columbia, Cincinnati Children's, and UTMB. Cash position declined to $146.8M (from $191.4M at year-end 2025); Q2 net loss was $(20.2)M ($(0.35)/share).
Why this rating
Early-stage commercial traction ($11.4M quarterly revenue = 4.2% of market cap) and regulatory milestone (CMS NTAP) are positive; however, cash burn ($44.6M in H1 2026), manufacturing yield issues (2 of 5 patients in Q2 not recognized), and small patient volume (12 total treatments in launch phase) offset gains. Modest progress relative to company size; not trajectory-changing yet.
See more from August 13, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.